MOR107 / Novartis - LARVOL DELTA

LP2, a stable lanthipeptide derived from cAng-(1-7), exerts myeloprotective action in mice. (PubMed, Eur J Haematol) - "LP2 exerts myeloprotective action with perspectives for continuation of its clinical development."

Journal • Preclinical • Hematological Disorders • Oncology

LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice. (PubMed, Peptides) - "LP2 acted synergistically with 5-FU and the EGFR inhibitor erlotinib. Taken together, the extremely low dose of LP2 at which antitumor activity is exerted, the synergism with selected drugs and, together with its excellent specificity, safety and stability, warrant further evaluation of LP2's inhibitory potential of colorectal cancer."

Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ATR

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake. (PubMed, Neurotherapeutics) - "This is the first demonstration of in vivo activity of an intranasally administered lanthipeptide. Consequently, M89b is a promising candidate for clinical application as a galanin-related peptide-based therapeutic."

Journal

First in Human Single Ascending Dose Study of MOR107 (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Alan Richardson

New P1 trial • Biosimilar